Vitamin C (ascorbic acid) 500 mg/capsule. Ingestion of 2 capsules (1000 mg) daily for 12 months.

Placebo capsule. Ingestion of 2 capsules daily for 12 months. Placebo will be prepared as capsules that look and taste identical to the vitamin C supplement capsules. The content of the placebo is lactose, potato starch, gelatin, magnesium stearate, and talc.

Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia-1

Cytopenia

Monotherapy with oral vitamin C supplementation to elevate plasma vitamin C level to the upper end of the physiological range.

Vitamin C (ascorbic acid)

Placebo

Nordic Council of Ministers (2012). Vitamin C. In Nordic Nutrition Recommendations (NNR) (Copenhagen), pp. 465-473

University of Southern California

Rigshospitalet

Herlev Hospital

Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies

Epigenetics, Vitamin C, and Abnormal Hematopoiesis - Role of Vitamin C in Epigenetic Regulation in Hematopoiesis Sub-Study on CCUS, Low-Risk MDS, and CMML-0/1

Mean change from baseline to 12 months in mutant allele burden as measured by the variant allele frequency (VAF) and number of mutations.

Mean change from baseline to 3 months in global 5-hmC/5-mC measured in hematopoietic stem cells is compared between the vitamin C group and the placebo group. In addition, the mean change from baseline in 5-hmC/5-mC at 12 months is compared between participants in the vitamin C arm with baseline plasma vitamin C level in the normal range vs. participants in the vitamin C arm with baseline plasma vitamin C level below the normal range.

Mean change from baseline to 12 months in 5-mC at promoters/enhancers/long terminal repeats, and other regulatory genomic regions of tumor suppressors/methylated driver genes/genes involved in hematopoietic development.

Mean change from baseline to 12 months in methylated histone H3 lysine at position 9 at promoters/enhancers/long terminal repeats, and other regulatory regions of tumor suppressors/methylated driver genes/genes involved in hematopoietic development.

Mean change from baseline to 12 months in plasma cytokine levels (e.g., IL-6, S100A9, etc.).

Mean change from baseline to 12 months in mRNA levels of tumor suppressor genes, oncogenes, epigenetic regulators, cytokines, and genes involved in hematopoietic development.

Mean change from baseline to 3 months in mRNA levels of tumor suppressor genes, oncogenes, epigenetic regulators, cytokines, and genes involved in hematopoietic development.

Number of serious adverse events and treatment-related adverse events as assessed by CTCAE v5.0. Adverse events, that are not considered serious or related to vitamin C intake, will not be recorded.

Percentage of participants with baseline plasma vitamin C level below the normal physiological range.

Mean change from baseline to 12 months in global 5-hmC/5-mC measured in hematopoietic stem cells is compared between the vitamin C group and the placebo group. In addition, the mean change from baseline in 5-hmC/5-mC at 12 months is compared between participants in the vitamin C arm with baseline plasma vitamin C level in the normal range vs. participants in the vitamin C arm with baseline plasma vitamin C level below the normal range.

Kirsten Grønbæk

Professor, MD, DMSc

Rigshospitalet, Denmark

Van Andel Research Institute

Imperial College London

University of Copenhagen

Zealand University Hospital

Technical University of Denmark

Prospective, randomized, placebo-controlled trial.

Randomization performed by the independent provider of study medication (Glostrup Pharmacy).

The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.

The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.

Iron Deficiency Anemia

Ferrous bis-glycinate

Ferrous glycine sulphate

Assiut university

The Effect of Iron Deficiency Anemia During Pregnancy

Ferrous Bis-glycinate Versus Ferrous Glycine Sulfate for the Treatment of Iron Deficiency Anemia During Pregnancy

difference in hemoglobin concentrations before and after treatment

Ahmed Mohamed Abbas

Assiut University

Acute Schizophrenia

niacinamide

pyridoxine

ascorbate

Beersheva Mental Health Center

Treatment of Acute Schizophrenia With Vitamin Therapy

The Treatment of Acute Schizophrenia With High Dose Niacinmide Plus Ascorbate Plus Pyridoxine Plus Centrum Forte vs. Centrum Forte Only as an Add-On to Risperidone and Dietary Counseling

ascorbate/diarré

Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies

The Effect of Iron Deficiency Anemia During Pregnancy

Treatment of Acute Schizophrenia With Vitamin Therapy

Den mest komplette database med medicinske urter understøttet af videnskab